MBX Biosciences (MBX) Stock Price, News & Analysis

Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Key Stats

• Today's Range: $10.94 to $12.11
• 50-Day Range: $9.73 to $15.49
• 52-Week Range: $4.81 to $27.50
• Volume: 327,239 shs
• Average Volume: 323,667 shs
• Market Capitalization: $372.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.63
• Consensus Rating: Buy

MBX Biosciences Stock Analysis - MarketRank™

MBX Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 458th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MBX Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MBX Biosciences are expected to grow in the coming year, from ($13.25) to ($2.30) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MBX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MBX Biosciences does not currently pay a dividend.

Dividend Growth

MBX Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MBX.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.57

News Sentiment

MBX Biosciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for MBX Biosciences this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for MBX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

2 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MBX Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

52.19% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

MBX Stock Analysis - Frequently Asked Questions

How have MBX shares performed this year?

MBX Biosciences' stock was trading at $18.43 at the beginning of the year. Since then, MBX shares have decreased by 39.6% and is now trading at $11.13.

How were MBX Biosciences' earnings last quarter?

MBX Biosciences, Inc. (NYSE:MBX) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.72) by $0.06.

When did MBX Biosciences IPO?

MBX Biosciences (MBX) raised $163 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 10,200,000 shares at $16.00 per share.

Who are MBX Biosciences' major shareholders?

Top institutional investors of MBX Biosciences include TD Asset Management Inc (0.51%), Platinum Investment Management Ltd. (0.34%) and Koa Wealth Management LLC (0.09%). Insiders that own company stock include Life Sciences X LP Frazier, Edward T Mathers, Carl L Gordon, P Kent Hawryluk and Ora H Pescovitz.
View institutional ownership trends.

How do I buy shares of MBX Biosciences?

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MBX Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:MBX
• Previous Symbol: NYSE:MBX
• CIK: 1776111
• Web: mbxbio.com
• Phone: (317) 659-0200
• Fax: N/A
• Employees: 36
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MBX Biosciences: $37.63
• High Price Target: $44.00
• Low Price Target: $30.00
• Potential Upside/Downside: +238.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,424,000
• Free Float: N/A
• Market Cap: $372.01 million
• Optionable: N/A
• Beta: N/A